Pfizer Inc. (NYSE:PFE) Shares Sold by Means Investment CO. Inc.

Means Investment CO. Inc. cut its position in Pfizer Inc. (NYSE:PFE - Free Report) by 43.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 37,066 shares of the biopharmaceutical company's stock after selling 27,907 shares during the period. Means Investment CO. Inc.'s holdings in Pfizer were worth $939,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of PFE. Trifecta Capital Advisors LLC grew its holdings in Pfizer by 35.4% during the first quarter. Trifecta Capital Advisors LLC now owns 3,659 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 956 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its holdings in Pfizer by 2.5% during the first quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 56,557 shares of the biopharmaceutical company's stock worth $1,426,000 after acquiring an additional 1,400 shares during the period. ORG Wealth Partners LLC grew its holdings in Pfizer by 2,701.6% during the first quarter. ORG Wealth Partners LLC now owns 59,226 shares of the biopharmaceutical company's stock worth $1,454,000 after acquiring an additional 57,112 shares during the period. Compass Capital Corp MA ADV grew its holdings in Pfizer by 1.2% during the first quarter. Compass Capital Corp MA ADV now owns 50,072 shares of the biopharmaceutical company's stock worth $1,253,000 after acquiring an additional 615 shares during the period. Finally, Adams Asset Advisors LLC boosted its position in Pfizer by 1.7% during the first quarter. Adams Asset Advisors LLC now owns 347,949 shares of the biopharmaceutical company's stock worth $8,817,000 after purchasing an additional 5,803 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $23.88 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market cap of $135.74 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The business's 50 day moving average price is $23.22 and its 200 day moving average price is $24.91.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.82 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.20%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.